Records containing: Vulvovaginal Signs and Symptoms
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-03-30Changes in the Impact of Genitourinary Syndrome of Menopause With a Novel Nonhormonal Vulvovaginal Gel Assessed by PROMs. Phase 2, Single Arm, Interventional, Longitudinal, Clinical Trial. Part of STOP GSM PROJECT.
-
CLINICAL_TRIALS study record update · 2026-03-09Vulvovaginal Graft-versus-Host Disease: Diagnosis and Microbiome Evaluation
-
CLINICAL_TRIALS study record update · 2025-09-15Effects of Ospemifene on Brain Activation Patterns in Women With Sexual Interest-arousal Disorders
-
CLINICAL_TRIALS study record update · 2025-08-19Women's Interventions for Sexual Health: WISH, Feasibility of a Factorial Design
-
CLINICAL_TRIALS study record update · 2024-01-30Effect of Factional CO2 Laser Treatment on Vaginal Symptoms and Sexual Dysfunction in Women With Systemic Sclerosis
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2022-08-10Clinical Evaluation of Fractional Bi-Polar Radio-Frequency for Symptoms of Stress Urinary Incontinence and Vulvovaginal Atrophy
-
CLINICAL_TRIALS study record update · 2022-01-11Retrospective Chart Review Study of Patients Treated With Votiva Device
-
CLINICAL_TRIALS study record update · 2020-12-09An Open-Label Uncontrolled Single Centre Study for the Evaluation of the Performance Characteristics (Efficacy and Safety) of the Dermal Filler MMG-23-04-2019 (Hyaluronic Acid 2,0%) for Female Intimate Area Hydration and Atrophy of the Vagina.